domingo, 6 de abril de 2014

CATALONIA -- Grífols goes on record for independence: "President, do not falter" - VilaWeb

Grífols goes on record for independence: "President, do not falter" - VilaWeb



Grífols goes on record for independence: "President, do not falter"

The multinational company Grífols is one of the principal strategic elements in the world, according to the United States

The president of the pharmaceutical multinational Grífols, Victor
Grífols, publicly expressed his support for the president of the
Generalitat, Artur Mas, in the process of sovereignty. "President, I
know you're having a hard time, that you are determined, and excuse me,
but... go for it, do not falter now," he said. The comments came during
the inauguration of a new Grífols plasma fractioning plant in Parets del
Vallès. "When an organization, whatever type it may be, has a clear
objective, a clear idea of where its future lies, any criticisms that
question its strategy or reason for being should not make it afraid,"
said Grífols.

Mas thanked Grífols for his "valor and courage" and
pointed out that the multinational invests in the United States, the
Spanish State, and in Catalonia. And then he added, "Despite the
apocalyptic messages that some people are offering, common sense will
end up prevailing in the economy."


The United States considers the Catalan pharmaceutical company one of
the three hundred strategic elements of the planet, listed in the Critical Foreign Dependencies Initiative,
elaborated by the Department of Homeland Security, and which includes
infrastructures, natural resoures, and private businesses. Grífols
appears on the 2009 version of the list which was leaked by WikiLeaks on
December 5, 2010.


Washington's interest in the pharmaceutical laboratory is due to the
Immune Globulin Intravenous (IGIV), a product derived from the treatment
of plasma and which has various therapeutic applications.


Grífols, with its subsidiaries in twenty countries, is defined as the
first company in Europe in the market of hemoderivatives and one of the
top five in the world. In 2009, they had sales of 913 million euros
($1,257,383,600 USD).


Here is a transcript of Mr. Grífols comments:


Let me say that when an organization, whatever type it may be, has a
clear objective, a clear idea of where its future lies, any criticisms
that question its strategy or reason for being should not make it
afraid. With steadfastness and determination, one can go very far. And
this last message, President, is for you in particular. I know you're
having a hard time, that you are determined, and excuse me, but... go
for it, do not falter now. Thank you.